Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: a cross-sectional study.
Stolbrink M, Ozoh OB, Halpin DMG, Nightingale R, Meghji J, Plum C, Allwood BW, Jayasooriya S, Mortimer K; Chronic Respiratory Diseases Medicines Survey Investigators Collaboration. Stolbrink M, et al. Thorax. 2024 Jun 14;79(7):676-679. doi: 10.1136/thorax-2023-221349. Thorax. 2024. PMID: 38760170 Free PMC article.
Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho.
Oyewusi L, Zeng C, Seung KJ, Mpinda S, Kunda M, Mitnick CD, Kanu M, Tamirat M, Makaka J, Mofolo M, Maime R, Maama L, Senyo N, Oguntoyinbo B, Mayombo L, Franke MF. Oyewusi L, et al. Glob Health Action. 2024 Dec 31;17(1):2305930. doi: 10.1080/16549716.2024.2305930. Epub 2024 Feb 2. Glob Health Action. 2024. PMID: 38305025 Free PMC article.
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis.
Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, Hewison C, Bastard M, Khan P, Seung KJ, Rich ML, Law S, Kikvidze M, Kirakosyan O, Miankou A, Thit P, Mamsa S, Janmohamed A, Melikyan N, Ahmed S, Vargas D, Binegdie AB, Temirova K, Oyewusi L, Philippe K, Vilbrun SC, Khan U, Huerga H, Franke MF; endTB Observational Study Team. Zeng C, et al. Among authors: oyewusi l. medRxiv [Preprint]. 2024 Jan 19:2024.01.18.24301453. doi: 10.1101/2024.01.18.24301453. medRxiv. 2024. PMID: 38293100 Free PMC article. Preprint.
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L. Patil SB, et al. Among authors: oyewusi l. Trials. 2023 Nov 30;24(1):773. doi: 10.1186/s13063-023-07701-6. Trials. 2023. PMID: 38037119 Free PMC article.
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
Zeng C, Mitnick CD, Hewison C, Bastard M, Khan P, Seung KJ, Rich ML, Atwood S, Melikyan N, Morchiladze N, Khachatryan N, Khmyz M, Restrepo CG, Salahuddin N, Kazmi E, Dahri AA, Ahmed S, Varaine F, Vilbrun SC, Oyewusi L, Gelin A, Tintaya K, Yeraliyeva LT, Hamid S, Khan U, Huerga H, Franke MF. Zeng C, et al. Among authors: oyewusi l. Int J Tuberc Lung Dis. 2023 Jan 1;27(1):34-40. doi: 10.5588/ijtld.22.0324. Int J Tuberc Lung Dis. 2023. PMID: 36853128 Free PMC article.
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. Guglielmetti L, et al. Among authors: oyewusi l. Trials. 2021 Sep 25;22(1):651. doi: 10.1186/s13063-021-05491-3. Trials. 2021. PMID: 34563240 Free PMC article.
Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB.
Cox V, McKenna L, Acquah R, Reuter A, Wasserman S, Vambe D, Ustero P, Udwadia Z, Triviño-Duran L, Tommasi M, Skrahina A, Seddon JA, Rodolfo R, Rich M, Padanilam X, Oyewusi L, Ohler L, Lungu P, Loveday M, Khan U, Khan P, Hughes J, Hewison C, Guglielmetti L, Furin J. Cox V, et al. Among authors: oyewusi l. Int J Tuberc Lung Dis. 2020 Nov 1;24(11):1134-1144. doi: 10.5588/ijtld.20.0330. Int J Tuberc Lung Dis. 2020. PMID: 33172520
12 results